Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2012

View Archived Issues

PaxVax presents phase I results on single-dose live oral cholera vaccine

A novel bispecific antibody shows tumor specificity in vivo

Lipoquin provides protection in murine model of pneumonic plague

Researchers at Bayer synthesize new cyclin-dependent kinase inhibitors

Oxford BioMedica provides update on ocular gene therapy candidates

FDA recommends continuation of Emmaus Medical's phase III sickle cell disease study

Astellas files sNDA for Tarceva in specific NSCLC subtype

European Commission approves Bayer's oral anticoagulant Xarelto for new indication

LEO Pharma's Picato gel receives European approval for actinic keratosis

Neovacs discloses final results from phase II TNF-alpha kinoid study

RNAi modifications: Progression from the bench to the clinic

Antisense morpholinos devised to treat spinal muscular atrophy

Dicerna's Dicer Substrate siRNA in lipid nanoparticles targets beta-catenin

Bayer Intellectual Property patents novel GCS activators

New C. difficile vaccines patented by Pfizer

GlaxoSmithKline synthesizes new bromodomain inhibitors

Ancora Pharmaceuticals presents new vaccines for Staphylococcus infection

New bispecific antibodies for cancer prepared by Genmab

Regen BioPharma begins preclinical study of HemaXellerate cell therapy

Atox Bio releases encouraging phase IIa topline results for AB-103

TMZ-POH has cytotoxic effects in temozolomide-resistant glioma cell lines

Preclinical study of H5N1 VLP vaccine shows cross-protection effects

European Commission approves Eliquis to prevent stroke in nonvalvular atrial fibrillation

Supernus' antiepileptic drug granted 3 years of market exclusivity in U.S.

XBiotech reports on interim analysis from phase II trial of monoclonal antibody

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...